Show simple item record

dc.contributor.authorDoi, Suhail AR
dc.contributor.authorFuruya-Kanamori, Luis
dc.contributor.authorToft, Egon
dc.contributor.authorMusa, Omran AH
dc.contributor.authorIslam, Nazmul
dc.contributor.authorClark, Justin
dc.contributor.authorThalib, Lukman
dc.date.accessioned2020-01-21T01:25:18Z
dc.date.available2020-01-21T01:25:18Z
dc.date.issued2019
dc.identifier.issn1467-7881
dc.identifier.doi10.1111/obr.12964
dc.identifier.urihttp://hdl.handle.net/10072/390673
dc.description.abstractPrevious randomized and observational studies on the efficacy of metformin in pregnancy to reduce incident gestational diabetes mellitus (GDM) in women at high risk (obesity, polycystic ovary syndrome [PCOS], or pregestational insulin resistance) have been conflicting and several groups are planning further randomized controlled trials (RCTs) to answer this question conclusively. This work assesses the efficacy of metformin in pregnancy to avert one outcome—incident GDM in women at high risk. We included RCTs comparing metformin with usual care or placebo controls in terms of incident GDM and recruiting women at high risk during early pregnancy. Eleven eligible trials enrolled 2370 adult women whose intervention arm consisted of metformin started at conception or before 20 weeks of gestation. Risk of GDM was similar in intervention compared with controls (risk ratio [RR] 1.03; 95% confidence interval [CI], 0.85‐1.24). The data were of sufficient quality meeting the criteria for consistency and directness. We conclude that metformin does not contribute to averting the GDM outcome in women at high risk when initiated in pregnancy. The evidence provided by this synthesis affirms that further broad clinical trials investigating this question are no longer needed.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherWiley
dc.publisher.placeUnited Kingdom
dc.relation.ispartofpagefrome12964: 1
dc.relation.ispartofpagetoe12964: 9
dc.relation.ispartofissue1
dc.relation.ispartofjournalObesity Reviews
dc.relation.ispartofvolume21
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchMedical and Health Sciences
dc.subject.fieldofresearchPsychology and Cognitive Sciences
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode11
dc.subject.fieldofresearchcode17
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsEndocrinology & Metabolism
dc.subject.keywordsgestational diabetes
dc.subject.keywordsinsulin resistance
dc.titleMetformin in pregnancy to avert gestational diabetes in women at high risk: Meta-analysis of randomized controlled trials
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationDoi, SAR; Furuya-Kanamori, L; Toft, E; Musa, OAH; Islam, N; Clark, J; Thalib, L, Metformin in pregnancy to avert gestational diabetes in women at high risk: Meta-analysis of randomized controlled trials, Obesity Reviews, 2019, 21 (1), pp. e12964: 1-e12964: 9
dcterms.dateAccepted2019-09-16
dc.date.updated2020-01-20T05:49:01Z
gro.hasfulltextNo Full Text
gro.griffith.authorThalib, Lukman


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record